Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?

Marie Amélie Heng (1) , Laetitia Padovani (2) , Philippe Dory-Lautrec (3) , Jean Claude Gentet (1) , Arnaud Verschuur (1) , Eddy Pasquier (4) , Dominique Figarella-Branger (5) , Didier Scavarda (6) , Nicolas André (4)

1 Service d'Hématologie et d'Oncologie pédiatrique
2 Service de Radiothérapie
3 Service de radiologie
4 CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie
5 Service d’Anatomopathologie
6 Service de Neurochirurgie pédiatrique

The association of bevacizumab and irinotecan has been shown to display a quick efficacy in low- grade glioma (LGG), but most patients relapse within months after cessation of therapy. From October 2012 to March 2014, four patients have been treated with irinotecan–bevacizumab followed by a metronomic maintenance with weekly vinblastine to try to prevent relapses. After a median follow- up of 23 months after the end of the bevacizumab–irinotecan induction, no patient relapsed. These observations suggest that maintenance chemotherapy with weekly vinblastine after an induction by irinotecan–bevacizumab can improve progression-free survival in children with LGG.

Domaines: Cancer; Médicaments; Immunothérapie; Pédiatrie; Neurobiologie

Marie Amélie Heng, Laetitia Padovani, Philippe Dory-Lautrec, Jean Claude Gentet, Arnaud Verschuur, et al.. Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?. Cancer Medicine, 2016, 5 (7), pp.1542-1545. ⟨10.1002/cam4.699⟩. ⟨hal-01478943⟩